Casdin Capital DNLI Position
Active4-Fund ConvergenceCasdin Capital increased their position in Denali Therapeutics Inc. (DNLI) in Q4 2025, holding $30.4M worth of shares across 1,840,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
DNLI is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for BIIB122 225 mg in 16 days (Apr 30, 2026), making the timing of Casdin's position particularly relevant.
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
10.0%
9.0 days to cover
Casdin Capital DNLI Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 1,840,000 | +950,000 | $30.4M |
| Q3 2025 | Held | 890,000 | — | $12.9M |
| Q2 2025 | Decreased | 890,000 | -100,000 | $12.5M |
| Q1 2025 | Held | 990,000 | — | $13.5M |
| Q4 2024 | Held | 990,000 | — | $20.2M |
| Q3 2024 | Decreased | 990,000 | -310,000 | $28.8M |
| Q2 2024 | Held | 1,300,000 | — | $30.2M |
| Q1 2024 | Held | 1,300,000 | — | $26.7M |
| Q4 2023 | Held | 1,300,000 | — | $27.9M |
| Q3 2023 | Held | 1,300,000 | — | $26.8M |
| Q2 2023 | Held | 1,300,000 | — | $38.4M |
| Q1 2023 | New | 1,300,000 | +1,300,000 | $30.0M |
Frequently Asked Questions
Does Casdin Capital own DNLI?
Yes. As of Q4 2025, Casdin Capital holds 1,840,000 shares of Denali Therapeutics Inc. (DNLI) valued at $30.4M. This data comes from their SEC 13F filing.
How many hedge funds own DNLI?
4 specialist biotech hedge funds currently hold DNLI, including Baker Bros. Advisors, Deerfield Management, Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy DNLI?
Casdin Capital's position in DNLI was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's DNLI position increasing or decreasing?
Casdin Capital increased their DNLI position in the most recent quarter, adding 950,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DNLICompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →